Bicara Therapeutics Inc. (BCAX)
NASDAQ: BCAX · Real-Time Price · USD
16.40
+0.52 (3.27%)
Oct 30, 2025, 1:13 PM EDT - Market open
Bicara Therapeutics Employees
Bicara Therapeutics had 55 employees as of December 31, 2024.
Employees
55
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,866,764
Market Cap
895.64M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 55 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BCAX News
- 17 days ago - Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC - GlobeNewsWire
- 2 months ago - Bicara Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus - Seeking Alpha
- 5 months ago - Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewsWire
- 5 months ago - Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025 - GlobeNewsWire
- 5 months ago - Bicara: Stock Decline On FICERA Abstract Release Creates Buying Opportunity - Seeking Alpha
- 5 months ago - Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting - GlobeNewsWire